Literature DB >> 17431714

Extranodal tumor extension to adjacent organs predicts a worse cause-specific survival in patients with papillary thyroid carcinoma.

Yasuhiro Ito1, Mitsuyoshi Hirokawa, Tomoo Jikuzono, Takuya Higashiyama, Yuuki Takamura, Akihiro Miya, Kaoru Kobayashi, Fumio Matsuzuka, Kanji Kuma, Akira Miyauchi.   

Abstract

BACKGROUND: We previously reported that massive extrathyroid extension has an independent prognostic value in patients with thyroid papillary carcinoma. However, tumor extension to adjacent organs can be observed not only in primary tumor but also in metastatic nodes. In this study we investigated the clinical significance of extranodal tumor extension to adjacent organs (nodal ex) in papillary thyroid carcinoma.
METHODS: We classified all cases into three categories based on the degree of nodal ex: nodal ex0, no apparent extranodal tumor extension; nodal ex1, hard metastatic nodes with perinodal growth extending to adjacent organs, which require separation of the nodes from the organs; and nodal ex2, metastatic nodes with perinodal growth completely invading the adjacent organs and requiring excision of nodes together with these organs. We investigated the clinical significance of each grade in 1,692 patients who underwent initial surgery for papillary carcinoma between 1987 and 1995.
RESULTS: The presence of nodal ex was significantly linked to various clinicopathological features such as male gender, N1b, large number of metastatic nodes, pT4a, and distant metastasis. On univariate analysis, patients with either nodal ex1 or ex2 showed significantly worse disease-free and cause-specific survival rates, although these rates did not differ between patients with nodal ex1 and those with nodal ex2. Furthermore, multivariate analysis demonstrated that nodal ex independently predicts worse cause-specific survival of these patients.
CONCLUSIONS: Presence of nodal ex significantly reflects the biologically aggressive behaviors of papillary carcinoma and has a prognostic value, especially for cause-specific survival of patients.

Entities:  

Mesh:

Year:  2007        PMID: 17431714     DOI: 10.1007/s00268-007-9042-2

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.282


  3 in total

1.  Patient-doctor decision-making about treatment within the consultation--a critical analysis of models.

Authors:  Veronika Wirtz; Alan Cribb; Nick Barber
Journal:  Soc Sci Med       Date:  2005-06-29       Impact factor: 4.634

2.  Developing, implementing, and evaluating decision support systems for shared decision making in patient care: a conceptual model and case illustration.

Authors:  Cornelia M Ruland; Suzanne Bakken
Journal:  J Biomed Inform       Date:  2002 Oct-Dec       Impact factor: 6.317

3.  Internet-based patient self-care: the next generation of health care delivery.

Authors:  June Forkner-Dunn
Journal:  J Med Internet Res       Date:  2003 Apr-Jun       Impact factor: 5.428

  3 in total
  20 in total

1.  Prognostic factors of papillary thyroid carcinoma vary according to sex and patient age.

Authors:  Yasuhiro Ito; Takumi Kudo; Yuuki Takamura; Kaoru Kobayashi; Akihiro Miya; Akira Miyauchi
Journal:  World J Surg       Date:  2011-12       Impact factor: 3.352

2.  Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5,768 patients with average 10-year follow-up.

Authors:  Yasuhiro Ito; Takumi Kudo; Kaoru Kobayashi; Akihiro Miya; Kiyoshi Ichihara; Akira Miyauchi
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

Review 3.  Pathologic reporting of lymph node metastases in differentiated thyroid cancer: a call to action for the College of American Pathologists.

Authors:  Mark L Urken; Jeffery I Mechanick; Jonathan Sarlin; Sophie Scherl; Bruce M Wenig
Journal:  Endocr Pathol       Date:  2014-09       Impact factor: 3.943

4.  Establishment of an intraoperative staging system (iStage) by improving UICC TNM classification system for papillary thyroid carcinoma.

Authors:  Yasuhiro Ito; Kiyoshi Ichihara; Hiroo Masuoka; Mitsuhiro Fukushima; Hiroyuki Inoue; Minoru Kihara; Chisato Tomoda; Takuya Higashiyama; Yuuki Takamura; Kaoru Kobayashi; Akihiro Miya; Akira Miyauchi
Journal:  World J Surg       Date:  2010-11       Impact factor: 3.352

5.  Pathologic features of metastatic lymph nodes identified from prophylactic central neck dissection in patients with papillary thyroid carcinoma.

Authors:  Hyoung Shin Lee; Chanwoo Park; Sung Won Kim; Woong Jae Noh; Soo Jin Lim; Bong Kwon Chun; Beom Su Kim; Jong Chul Hong; Kang Dae Lee
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-01-12       Impact factor: 2.503

6.  A response to the "call to action" on pathologic reporting of lymph node metastases in differentiated thyroid cancer from the college of american pathologists.

Authors:  Raja R Seethala; Thomas P Baker; Jean F Simpson
Journal:  Endocr Pathol       Date:  2014-12       Impact factor: 3.943

Review 7.  Nodal metastases in thyroid cancer: prognostic implications and management.

Authors:  Laura Y Wang; Ian Ganly
Journal:  Future Oncol       Date:  2016-03-07       Impact factor: 3.404

Review 8.  Crucial parameters in thyroid carcinoma reporting - challenges, controversies and clinical implications.

Authors:  Bin Xu; Ronald A Ghossein
Journal:  Histopathology       Date:  2018-01       Impact factor: 5.087

9.  Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression.

Authors:  Miriam Lango; Douglas Flieder; Rodrigo Arrangoiz; Colleen Veloski; Jian Q Yu; Tianyu Li; Barbara Burtness; Ranee Mehra; Tom Galloway; John A Ridge
Journal:  Thyroid       Date:  2013-09       Impact factor: 6.568

10.  Urinary neopterin levels in patients with thyroid cancer.

Authors:  Serap Soytac Inancli; Sedat Caner; Fevzi Balkan; Abbas Ali Tam; Gulnur Guler; Reyhan Ersoy; Bekir Cakir
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2014-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.